KIDS Stock Analysis: Orthopediatrics | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 811m USD | 12M Return: 87.4% | US68752L1008 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.53M
Qual. Beats: 0
Rev. Trend: 97.9%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
OrthoPediatrics Corp. (NASDAQ: KIDS) is a medical device company that designs, develops, and markets anatomically appropriate implants, instruments, and braces specifically for children with orthopedic conditions. Its product portfolio spans three main categories: pediatric trauma and deformity correction, scoliosis procedures, and sports medicine and other products, featuring a wide range of branded systems and platforms such as PediLoc, RESPONSE Spine, the Fassier-Duval Telescopic Intramedullary System, and the Boston Brace 3D. The company serves the pediatric orthopedic market, including pediatric orthopedic surgeons and caregivers, in both the United States and international markets. Founded in 2006 and headquartered in Warsaw, Indiana, OrthoPediatrics is a small-cap ($501M USD) health care supplies company that listed on NASDAQ in October 2017.
OrthoPediatrics operates in a specialized niche within the broader orthopedic device industry, which is largely dominated by large-cap manufacturers focused on adult populations. As a pure-play pediatric orthopedic company, its business model depends on surgeon relationships, recurring procedure-based revenue, and ongoing regulatory clearances and approvals from the U.S. Food and Drug Administration (FDA) for new and modified devices. Its broad product portfolio, which spans implants, instruments, and bracing, allows it to serve a wide range of procedures and patient ages within childrens orthopedics.
- Scoliosis and trauma segment revenue drives double-digit domestic growth
- Operating losses persist as salesforce expansion and acquisitions pressure margins
- International expansion lifts geographic revenue mix with European momentum
| Net Income: -33.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 6.59 > 1.0 |
| NWC/Revenue: 74.81% < 20% (prev 93.50%; Δ -18.68% < -1%) |
| CFO/TA 0.02 > 3% & CFO 12.5m > Net Income -33.9m |
| Net Debt (56.1m) to EBITDA (2.43m): 23.05 < 3 |
| Current Ratio: 4.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.2m) vs 12m ago 3.13% < -2% |
| Gross Margin: 73.76% > 18% (prev 71.73%; Δ 2.03% > 0.5%) |
| Asset Turnover: 52.69% > 50% (prev 46.08%; Δ 6.61% > 0%) |
| Interest Coverage Ratio: -2.20 > 6 (EBIT TTM -20.2m / Interest Expense TTM 9.18m) |
| A: 0.39 (Total Current Assets 253.2m - Total Current Liabilities 55.6m) / Total Assets 509.1m |
| B: -0.59 (Retained Earnings -299.0m / Total Assets 509.1m) |
| C: -0.04 (EBIT TTM -20.2m / Avg Total Assets 501.3m) |
| D: 2.00 (Book Value of Equity 339.4m / Total Liabilities 169.7m) |
| Altman-Z'' = 2.46 = A |
| DSRI: 1.00 (Receivables 59.5m/51.3m, Revenue 264.1m/227.4m) |
| GMI: 0.97 (GM 71.73% / 73.76%) |
| AQI: 1.03 (AQ_t 0.41 / AQ_t-1 0.40) |
| SGI: 1.16 (Revenue 264.1m / 227.4m) |
| TATA: -0.09 (NI -33.9m - CFO 12.5m) / TA 509.1m) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of October 31, 2026, the stock is trading at USD 30.87 with a total of 569,925 shares traded. Over the past week, the price has changed by +26.00%, over one month by +35.63%, over three months by +53.51% and over the past year by +87.43%.
Current recommended Stop Loss: 29.00 (which is 6.1% or 1.3 ATR below the current price).
Orthopediatrics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy KIDS.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30.3 | -2% |
P/S = 2.1524
P/B = 1.8327
Revenue TTM = 264.1m USD
EBIT TTM = -20.2m USD
EBITDA TTM = 2.43m USD
Long Term Debt = 99.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 174k USD (from shortTermDebt, last quarter)
Debt = 100.3m USD (corrected: LT Debt 99.8m + ST Debt 174k) + Leases 320k
Net Debt = 56.1m USD (calculated: Debt 100.3m - CCE 44.2m)
Enterprise Value = 867.2m USD (811.1m + Debt 100.3m - CCE 44.2m)
Interest Coverage Ratio = -2.20 (Ebit TTM -20.2m / Interest Expense TTM 9.18m)
EV/FCF = 272.7x (Enterprise Value 867.2m / FCF TTM 3.18m)
FCF Yield = 0.37% (FCF TTM 3.18m / Enterprise Value 867.2m)
FCF Margin = 1.20% (FCF TTM 3.18m / Revenue TTM 264.1m)
Net Margin = -12.83% (Net Income TTM -33.9m / Revenue TTM 264.1m)
Gross Margin = 73.76% ((Revenue TTM 264.1m - Cost of Revenue TTM 69.3m) / Revenue TTM)
Gross Margin QoQ = 74.28% (prev 74.27%)
Tobins Q-Ratio = 1.70 (Enterprise Value 867.2m / Total Assets 509.1m)
Interest Expense / Debt = 9.15% (Interest Expense 9.18m / Debt 100.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -16.0m (EBIT -20.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.55 (Total Current Assets 253.2m / Total Current Liabilities 55.6m)
Debt / Equity = 0.30 (Debt 100.3m / totalStockholderEquity, last quarter 339.4m)
Debt / EBITDA = 23.05 (Net Debt 56.1m / EBITDA 2.43m)
Debt / FCF = 17.64 (Net Debt 56.1m / FCF TTM 3.18m)
Total Stockholder Equity = 342.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.76% (Net Income -33.9m / Total Assets 509.1m)
RoE = -9.91% (Net Income TTM -33.9m / Total Stockholder Equity 342.1m)
RoCE = -4.58% (EBIT -20.2m / Capital Employed (Equity 342.1m + L.T.Debt 99.8m))
RoIC = -3.63% (negative operating profit) (NOPAT -16.0m / Invested Capital 440.4m)
WACC = 8.17% (E(811.1m)/V(911.4m) * Re(8.29%) + D(100.3m)/V(911.4m) * Rd(9.15%) * (1-Tc(0.21)))
Discount Rate = 8.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.10 | Cagr: 1.91%
[DCF] Terminal Value 75.44% ; FCFF base≈3.18m ; Y1≈3.19m ; Y5≈3.38m
[DCF] Fair Price = N/A (negative equity: EV 52.6m - Net Debt 56.1m = -3.48m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.31 | # QB: 0
Revenue Correlation: 97.92 | Revenue CAGR: 21.78% | SUE: 3.98 | # QB: 2
EPS current Quarter (2027-03-31): EPS=-0.34 | Chg30d=-24.32% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.09 | Chg30d=+0.00% | Revisions=-17% | GrowthEPS=-9.2% | GrowthRev=+14.9%
EPS next Year (2027-12-31): EPS=-0.85 | Chg30d=-20.42% | Revisions=+17% | GrowthEPS=+21.7% | GrowthRev=+12.1%
[Analyst] Revisions Ratio: +0% (up=4, down=4)